FormulaFolio Investments LLC Purchases Shares of 3,449 Repligen Co. (NASDAQ:RGEN)


Share on StockTwits

FormulaFolio Investments LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the 4th quarter, HoldingsChannel reports. The firm purchased 3,449 shares of the biotechnology company’s stock, valued at approximately $661,000.

Other institutional investors have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Repligen by 16.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,584 shares of the biotechnology company’s stock worth $1,262,000 after buying an additional 948 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Repligen by 0.3% in the fourth quarter. Northern Trust Corp now owns 411,373 shares of the biotechnology company’s stock worth $78,832,000 after buying an additional 1,164 shares during the last quarter. Thornburg Investment Management Inc. acquired a new position in Repligen in the 4th quarter worth about $13,904,000. Stifel Financial Corp raised its holdings in Repligen by 51.6% in the 4th quarter. Stifel Financial Corp now owns 10,466 shares of the biotechnology company’s stock worth $2,006,000 after purchasing an additional 3,561 shares during the period. Finally, Capital Advisory Group Advisory Services LLC raised its holdings in Repligen by 61.5% in the 4th quarter. Capital Advisory Group Advisory Services LLC now owns 5,603 shares of the biotechnology company’s stock worth $1,074,000 after purchasing an additional 2,133 shares during the period. Institutional investors and hedge funds own 84.33% of the company’s stock.

NASDAQ:RGEN opened at $201.31 on Thursday. The firm has a market cap of $11.03 billion, a PE ratio of 245.50, a price-to-earnings-growth ratio of 4.18 and a beta of 0.94. The stock has a fifty day moving average price of $199.72 and a 200 day moving average price of $191.31. Repligen Co. has a 12-month low of $94.52 and a 12-month high of $228.84. The company has a current ratio of 13.67, a quick ratio of 12.13 and a debt-to-equity ratio of 0.21.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, February 23rd. The biotechnology company reported $0.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.21. Repligen had a return on equity of 6.58% and a net margin of 13.40%. The company had revenue of $108.65 million for the quarter, compared to analysts’ expectations of $93.89 million. Equities analysts forecast that Repligen Co. will post 1.44 EPS for the current year.

In other news, VP Ralf Kuriyel sold 2,075 shares of Repligen stock in a transaction dated Thursday, March 4th. The stock was sold at an average price of $192.00, for a total transaction of $398,400.00. Following the sale, the vice president now owns 26,940 shares in the company, valued at $5,172,480. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas F. Ryan, Jr. sold 1,000 shares of Repligen stock in a transaction dated Wednesday, March 3rd. The stock was sold at an average price of $205.00, for a total value of $205,000.00. Following the sale, the director now owns 2,464 shares in the company, valued at approximately $505,120. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,022 shares of company stock worth $8,982,858. 1.70% of the stock is owned by insiders.

RGEN has been the subject of several research analyst reports. Craig Hallum raised their price target on Repligen from $245.00 to $251.00 and gave the stock a “buy” rating in a research report on Thursday, February 25th. SVB Leerink raised their price target on Repligen from $220.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 3rd. Finally, Zacks Investment Research lowered Repligen from a “strong-buy” rating to a “hold” rating and set a $200.00 price target for the company. in a research report on Tuesday, January 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Repligen currently has an average rating of “Buy” and an average target price of $203.80.

Repligen Company Profile

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Featured Article: Oversold

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.